CEBIOTEX receives approval to initiate a paediatric phase II clinical trial for locally resectable abdominal tumours

We are excited to share that the clinical trial to evaluate the safety, pharmacokinetics and efficacy of CEB-01 in locally resectable abdominal tumours of children has been green lighted by the regulatory authorities. This is a basket trial designed for pediatric patients under 18 years of age diagnosed with de novo or recurrent soft tissue sarcoma, neuroblastoma, or other rare tumors such as Wilms’ tumor or germ cell tumors. 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 It marks the first time that the potent active substance SN-38 is being evaluated in these patients as a local chemotherapy, with the goal of controlling tumor recurrence and addressing an unmet medical need. This step brings us closer to delivering new therapeutic options to children with rare cancers. 𝗧𝗵𝗮𝗻𝗸 𝗬𝗼𝘂 This milestone reflects the commitment to developing innovative surgical treatments for children of our team and collaborators in Hospital Sant Joan de Déu Barcelona , i4KIDS I i4KIDS-EUROPE and Ship2B Ventures . You might also be interested in Poster Presentation at ASCO 2024 Annual Meeting Read more La Vanguardia: “Cebiotex, al alza” Click here to read the online article. Read more Tech Barcelona - Pier 07 Via Laietana, 26, entresuelo. 08003, Barcelona. [email protected] cebiotex Legal notice Privacy policy About cookies

The release as fetched from its publisher. cebiotex.com ↗